Immuno-oncology (cancer immunotherapy), describes the process of utilizing the patient's own immune system to fight cancer. In the last decade, immuno-oncology has emerged as an exciting new approach to cancer treatment because of its specificity, adaptability and durability. One of the key areas within this field is a new class of proteins called immune checkpoints, such as PD-1 and CTLA-4 among others, which could enable cancer cells to hide from the immune system by modulating T cell signaling. Immune-checkpoints are being studied extensively as a new type of targets for cancer immunotherapy.
GenScript provides the One-Stop Platform to accelerate your immuno-oncology research, including numerous neutralizing immune checkpoint antibodies and anti-idiotypes (IDs), stable cell lines expressing immuno-oncology proteins at high levels, a wide range of purified recombinant proteins involved in immuno-signaling pathways, together with assay platforms for drug discovery and development.
|Immune Checkpoint Antibodies
GenScript provides multifunctional immune checkpoint antibody products to facilitate your immunotherapy research.
|Immuno-Oncology Recombination Proteins
The high-quality Immune Checkpoint Proteins in GenScript can support many kinds of researches in immune-oncology field
|ADCC & CDC assays
By implementing strict QC standards, GenScript provides the assurance of the efficacy and potency profiles of your therapeutic antibodies.
|Stable Cell Lines for Immuno-Oncology Research (CellPower™)
Both immune checkpoints and oncogene expressed stable cell lines are supplied;
|Tumor Cell Line Profiling
OncoProfiler and XenoProfiler not only provide efficacy data in human tumor cell lines, but also ensure translation of efficacy from in vitro to in vivo models.
Support PK and immunogenicity study of biosimilars